

EXOPULSE Mollii Suit Study Summaries

The summaries are organized in three levels depending on the detail of information. The overview table (Level 1) lists all the relevant publications dealing with a particular product (topic) and health condition, as well as researched contributions to the ICF categorises (e.g. Body Function& Structure, Activity, etc. and associated sub-categories). By clicking on individual categories, a summary of all the literature dealing with that category will open (Level 2).

For those interested to learn more about individual studies, a summary of the study can be obtained by clicking on the relevant reference (Level 3).

| Reference | | | | Category | | | | | | | | | |
|----------------------|-------|--------------|-----------------|----------------------------|------|------------|------------------------|------------------------|----------------|----------|-------------------|-------------|--|
| Author | Year | Indication | Popu- lation | Body Functions & Structure | | | | | Activity | | Participation | Environment | |
| Chronic Pain | | | | Level 2 | Pain | Spasticity | Physiological Function | Psychological Function | General Health | Activity | Mobility & Safety | ADLs | Participation, Preference, Satisfaction, QoL |
| <u>Rubio-Zarapuz</u> | 2024d | Fibromyalgia | Adults | | | | x | | | x | | | |
| <u>Rubio-Zarapuz</u> | 2024a | Fibromyalgia | Adults | | | | | | x | | | | |
| <u>Rubio-Zarapuz</u> | 2024b | Fibromyalgia | Adults | x | | | | | x | | | | |
| <u>Rubio-Zarapuz</u> | 2024c | Fibromyalgia | Adults | x | | | | | x | x | x | | |
| <u>Mattar</u> | 2024 | Fibromyalgia | Adults | x | | | | x | | | | x | |
| <u>Riachi</u> | 2023 | Fibromyalgia | Adults | x | | | | | | | | | |
| <u>Rubio-Zarapuz</u> | 2023 | Fibromyalgia | Adults | x | | | | | x | x | x | | |
| Total number: 7 | | | | 5 | 0 | 1 | 1 | 4 | 3 | 2 | 0 | 1 | 0 |

| Reference | | | | Category | | | | | | | | | | |
|-------------------|------|-------------------------------------|------------------|----------------------------|------------------------|------------------------|----------------|----------|-------------------|------|--|---------------|-------------|--|
| Author | Year | Indication | Popu- lation | Body Functions & Structure | | | | | Activity | | | Participation | Environment | |
| Spasticity | | Level 2 | Pain | Spasticity | Physiological Function | Psychological Function | General Health | Activity | Mobility & Safety | ADLs | Participation, Preference, Satisfaction, QoL | | | |
| <u>Ayache</u> | 2025 | MS | Adults | x | x | | x | | x | | x | x | | |
| <u>Torabi</u> | 2025 | Cerebral Palsy (CP) | Children | | x | x | | | x | x | | | | |
| <u>Weller</u> | 2025 | Cerebral Palsy (CP) | Children | | x | x | | x | | x | | x | | |
| <u>Perpetuini</u> | 2024 | Cerebral Palsy (CP) | Children | | x | | | | x | | | x | | |
| <u>Perpetuini</u> | 2023 | CP, Stroke, Parkinson, Fibromyalgia | Children, Adults | x | x | x | | x | x | x | | x | | |
| <u>Hahn</u> | 2023 | CP, MS, Stroke | Children, Adults | x | | | | | x | x | | x | | |
| Total number: 6 | | | | 3 | 5 | 3 | 1 | 2 | 4 | 5 | 0 | 5 | 0 | |